IP Library › Granted Patent US 11,306,295
Granted Patent B2
US 11,306,295 · App. 16/494,311 · Granted Apr 19, 2022

Heat-resistant luciferase

Inventors: Ayumi Hori (Ibaraki, JP); Yutaka Yamagishi (Tokyo, JP)
Assignees: TOYO B-NET CO., LTD.; TOYO INK SC HOLDINGS CO., LTD.
C12N9/0069C12N15/70C12Q1/66C12Y113/12007G01N21/763
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,306,295
App. No.
16/494,311
Granted
Apr 19, 2022
Kind
B2
Abstract

A new thermostable luciferase of the following mutant luciferase (a) or (b): (a) a mutant of a wild-type luciferase comprising the amino acid sequence of SEQ ID NO: 1, wherein phenylalanine at position 292 and/or phenylalanine at position 294 in the amino acid sequence of SEQ ID NO: 1 is substituted with another amino acid; or (b) a mutant of a luciferase having 93% or more homology with the amino acid sequence of SEQ ID NO: 1, wherein in the amino acid sequence of the mutant, the amino acid at a site corresponding to position 292 and/or position 294 in the amino acid sequence of SEQ ID NO: 1 is substituted with another amino acid.

Claims (13)

1. A thermostable luciferase of the following (a) or (b):

(a) a luciferase comprising the amino acid sequence of SEQ ID NO: 1, wherein phenylalanine at position 292 in the amino acid sequence of SEQ ID NO: 1 is substituted with glycine, alanine, valine, leucine, isoleucine, methionine, glutamine, glutamic acid, lysine, arginine, or histidine, or wherein phenylalanine at position 292 and phenylalanine at position 294 in the amino acid sequence of SEQ ID NO: 1 are substituted with glycine, alanine, valine, leucine, isoleucine, methionine, glutamine, glutamic acid, lysine, arginine, or histidine; or

(b) a luciferase having 93% or more sequence identity to the amino acid sequence of SEQ ID NO: 1 with the exception of the amino acid corresponding to residue at position 292 has the substitution of glycine, alanine, valine, leucine, isoleucine, methionine, glutamine, glutamic acid, lysine, arginine, or histidine or with the exception of the amino acid corresponding to residue at position 292 and position 294 have the substitution of glycine, alanine, valine, leucine, isoleucine, methionine, glutamine, glutamic acid, lysine, arginine, or histidine,

wherein said thermostable luciferase has increased thermostability as compared to a wild-type luciferase.

2. The thermostable luciferase of claim 1 , wherein the luciferase having 93% or more sequence identity to the amino acid sequence of SEQ ID NO: 1 further comprises at least one substitution at an amino acid residue selected from the group consisting of alanine corresponding to position 215, glutamic acid corresponding to position 354, and phenylalanine corresponding to position 215, glutamic acid corresponding to position 465 in the amino acid sequence of SEQ ID NO: 1.

3. A kit comprising the thermostable luciferase according to of claim 1 .

4. A method for conducting a bioluminescence assay comprising:

providing the thermostable luciferase of claim 1 conjugated with a target protein;

measuring a light emitted by a reaction between said thermostable luciferase conjugated with a target protein and a luminescent substrate.

5. An N-terminal fragment of a thermostable luciferase of the following (a) or (b)

(a) a luciferase comprising the amino acid sequence of SEQ ID NO: 1, wherein phenylalanine at position 292 in the amino acid sequence of SEQ ID NO: 1 is substituted with glycine, alanine, valine, leucine, isoleucine, methionine, glutamine, glutamic acid, lysine, arginine, or histidine, or wherein phenylalanine at position 292 and phenylalanine at position 294 in the amino acid sequence of SEQ ID NO: 1 are substituted with glycine, alanine, valine, leucine, isoleucine, methionine, glutamine, glutamic acid, lysine, arginine, or histidine; or

(b) a luciferase having 93% or more sequence identity to the amino acid sequence of SEQ ID NO: 1 with the exception of the amino acid corresponding to residue at position 292 has the substitution of glycine, alanine, valine, leucine, isoleucine, methionine, glutamine, glutamic acid, lysine, arginine, or histidine or with the exception of the amino acid corresponding to residue at position 292 and position 294 have the substitution of glycine, alanine, valine, leucine, isoleucine, methionine, glutamine, glutamic acid, lysine, arginine, or histidine,

wherein the N-terminal fragment comprises position 292 of the amino acid sequence of SEQ ID NO: 1, and wherein said thermostable luciferase has increased thermostability as compared to a wild-type luciferase.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2019
From: HORI, AYUMI; YAMAGISHI, YUTAKA
To: TOYO B-NET CO., LTD.; TOYO INK SC HOLDINGS CO., LTD.
Reel/Frame 050439/0168 →
Priority Claims (1)
JP JP2017-052502 · Mar 17, 2017 · national
Continuity (1)
Related Publication 20200017840A1 · Jan 16, 2020
Cited By (1)
US 12,435,322